Thumbnail Image

Splicing genomics events in cervical cancer: Insights for henotypic stratification and biomarker potency

Francies, F.Z.
Bassa, S.
Chatziioannou, A.
Kaufmann, A.M.
Dlamini, Z.
Gynaecological cancers are attributed to the second most diagnosed cancers in women after breast cancer. On a global scale, cervical cancer is the fourth most common cancer and the most common cancer in developing countries with rapidly increasing mortality rates. Human papillomavirus (HPV) infection is a major contributor to the disease. HPV infections cause prominent cellular changes including alternative splicing to drive malignant transformation. A fundamental characteristic attributed to cancer is the dysregulation of cellular transcription. Alternative splicing is regulated by several splicing factors and molecular changes in these factors lead to cancer mechanisms such as tumour development and progression and drug resistance. The serine/arginine-rich (SR) proteins and heterogeneous ribonucleoproteins (hnRNPs) have prominent roles in modulating alternative splicing. Evidence shows molecular alteration and expression levels in these splicing factors in cervical cancer. Furthermore, aberrant splicing events in cancer-related genes lead to chemo- and radioresistance. Identifying clinically relevant modifications in alternative splicing events and splicing variants, in cervical cancer, as potential biomarkers for their role in cancer progression and therapy resistance is scrutinised. This review will focus on the molecular mechanisms underlying the aberrant splicing events in cervical cancer that may serve as potential biomarkers for diagnosis, prognosis, and novel drug targets.
Journal Title
Journal ISSN
Volume Title
Research Projects
Organizational Units
Journal Issue
SR proteins,hnRNP,Alternative splicing,Biomarkers,Cervical cancer,Drug resistance,SDG-03 Good health and well-being
Francies FZ, Bassa S, Chatziioannou A, Kaufmann AM, Dlamini Z. Splicing Genomics Events in Cervical Cancer: Insights for Phenotypic Stratification and Biomarker Potency. Genes (Basel). 2021 Jan 20;12(2):130. doi: 10.3390/genes12020130.
Embedded videos